Active, not recruitingPhase 2NCT04977024

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Studying Plasma cell leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
GeoVax, Inc.
Principal Investigator
Chief Medical Officer
GeoVax, Inc.
Intervention
COVID-19 Vaccine(biological)
Enrollment
63 target
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04977024 on ClinicalTrials.gov

Other trials for Plasma cell leukemia

Additional recruiting or active studies for the same condition.

See all trials for Plasma cell leukemia

← Back to all trials